Unknown

Dataset Information

0

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

ABSTRACT:

SUBMITTER: Tolaney SM 

PROVIDER: S-EPMC8342577 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
| S-EPMC5313267 | biostudies-literature
Unknown Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.
| S-EPMC8387440 | biostudies-literature
Unknown Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
| S-EPMC4237755 | biostudies-literature
Unknown TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
| S-EPMC4451173 | biostudies-literature
Unknown A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
| S-EPMC6656474 | biostudies-literature
Unknown Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.
| S-EPMC5935675 | biostudies-other
Unknown Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
| S-EPMC5521206 | biostudies-literature
Unknown A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
| S-EPMC4847806 | biostudies-literature
Unknown A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
| S-EPMC7873338 | biostudies-literature
Unknown Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.
| S-EPMC5907662 | biostudies-literature